ArriVent BioPharma (NASDAQ:AVBP) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright initiated coverage on shares of ArriVent BioPharma (NASDAQ:AVBP) in a report published on Tuesday, MarketBeat reports. The firm issued a buy rating and a $25.00 price target on the stock. HC Wainwright also issued estimates for ArriVent BioPharma’s Q1 2024 earnings at ($1.25) EPS, Q2 2024 earnings at ($0.64) EPS, Q3 2024 earnings at ($0.67) EPS, Q4 2024 earnings at ($0.70) EPS, FY2024 earnings at ($3.03) EPS, Q1 2025 earnings at ($0.73) EPS, Q2 2025 earnings at ($0.76) EPS, Q3 2025 earnings at ($0.79) EPS, Q4 2025 earnings at ($0.82) EPS and FY2025 earnings at ($3.09) EPS.

AVBP has been the subject of several other research reports. Jefferies Financial Group started coverage on ArriVent BioPharma in a report on Tuesday, February 20th. They issued a buy rating and a $35.00 price objective for the company. The Goldman Sachs Group assumed coverage on shares of ArriVent BioPharma in a research report on Tuesday, February 20th. They issued a buy rating and a $27.00 price target on the stock. Finally, Citigroup started coverage on shares of ArriVent BioPharma in a research note on Tuesday, February 20th. They set a buy rating and a $30.00 price target on the stock.

ArriVent BioPharma Stock Performance

AVBP opened at $17.23 on Tuesday. ArriVent BioPharma has a twelve month low of $14.35 and a twelve month high of $25.95. The company has a 50-day moving average of $18.02.

Institutional Investors Weigh In On ArriVent BioPharma

An institutional investor recently bought a new position in ArriVent BioPharma stock. BNP Paribas Financial Markets bought a new position in ArriVent BioPharma, Inc. (NASDAQ:AVBP) during the 1st quarter, according to its most recent filing with the SEC. The institutional investor bought 4,659 shares of the company’s stock, valued at approximately $83,000. 9.48% of the stock is currently owned by institutional investors and hedge funds.

ArriVent BioPharma Company Profile

ArriVent BioPharma, Inc operates as a clinical-stage biopharmaceutical company that engages in the identification, development, and commercialization of medicines for the unmet medical needs of patients with cancers in the United States. It also engages in the development and commercialization of targeted cancer therapies for non-small cell lung cancer (NSCLC) and other solid tumors.